- Home
- LSF vs IVVD Comparison
LSF vs IVVD Comparison
Compare LSF & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- IVVD
- Stock Information
- Founded
- LSF 2015
- IVVD 2020
- Country
- LSF United States
- IVVD United States
- Employees
- LSF N/A
- IVVD N/A
- Industry
- LSF Packaged Foods
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- IVVD Health Care
- Exchange
- LSF Nasdaq
- IVVD Nasdaq
- Market Cap
- LSF 65.5M
- IVVD 69.0M
- IPO Year
- LSF 2020
- IVVD 2021
- Fundamental
- Price
- LSF $6.35
- IVVD $0.74
- Analyst Decision
- LSF Strong Buy
- IVVD Strong Buy
- Analyst Count
- LSF 2
- IVVD 3
- Target Price
- LSF $12.00
- IVVD $5.85
- AVG Volume (30 Days)
- LSF 26.2K
- IVVD 1.4M
- Earning Date
- LSF 08-06-2025
- IVVD 08-13-2025
- Dividend Yield
- LSF N/A
- IVVD N/A
- EPS Growth
- LSF N/A
- IVVD N/A
- EPS
- LSF N/A
- IVVD N/A
- Revenue
- LSF $45,040,358.00
- IVVD $36,688,000.00
- Revenue This Year
- LSF $23.40
- IVVD $446.60
- Revenue Next Year
- LSF $20.11
- IVVD $112.63
- P/E Ratio
- LSF N/A
- IVVD N/A
- Revenue Growth
- LSF 25.04
- IVVD N/A
- 52 Week Low
- LSF $3.40
- IVVD $0.35
- 52 Week High
- LSF $10.90
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- LSF 48.20
- IVVD 46.02
- Support Level
- LSF $6.03
- IVVD $0.71
- Resistance Level
- LSF $6.74
- IVVD $0.77
- Average True Range (ATR)
- LSF 0.37
- IVVD 0.06
- MACD
- LSF 0.01
- IVVD -0.01
- Stochastic Oscillator
- LSF 53.33
- IVVD 34.26
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.